Amgen is no exception to this dynamic. Although 2017's Tax Cuts and Jobs Act spurred the company to build a handful of new ...

As global markets experience a surge in optimism following a U.S.-China tariff pause and cooling inflation, investors are keenly observing the potential impacts on growth sectors. In this environment, ...

The robust performance of two major Hong Kong stock listings this week has raised hopes that a small group of elite Chinese ...

J&J’s JNJ stock has declined 6.4% in the past three months. J&J faces several challenges, including slowing sales in the ...

China will provide a more efficient, transparent and predictable regulatory environment to support technology firms listing ...

Peter Lu, at McDermott Will & Emery discusses China’s opening of its health industry to international investors ...

Amid a backdrop of easing trade tensions between the U.S. and China, global markets have experienced a notable rally, with ...

As technology continues to advance, the integration of AI into various aspects of the pharmaceutical industry will undeniably drive innovation, improve patient outcomes, and reshape the future of ...

President Donald Trump signed an executive order Monday that he said will slash drug prices by approximately 59% or more ...

Global markets have recently experienced a positive shift, with U.S. stocks rallying on news of a temporary suspension in ...

3SBio's shares surged 32% to 19.18 Hong Kong dollars, equivalent to US$2.45, on Tuesday after the Chinese company said it would receive an upfront payment of US$1.25 billion and potential milestone ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...